To the authors of "Efficacy of Novel Antistaphylococcal Ectolysin P128 in a Rat Model of Methicillin-Resistant Staphylococcus aureus Bacteremia"


I appreciate your work establishing a bacteremia model in rats in your paper "Efficacy of Novel Antistaphylococcal Ectolysin P128 in a Rat Model of Methicillin-Resistant Staphylococcus aureus Bacteremia". I am interested in studying the effect of a novel drug, and using your model as guidance. 

I was wondering if you could kindly provide me with details of the criteria you used for deciding the humane endpoint in your study (body weight, motility observations etc?)? 


Best regards, Caroline Søgaard